The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

NCT06611904 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether a combination of dulaglutide and dapagliflozin improves blood vessel function in adults with type 2 diabetes and kidney-related issues, compared to a different diabetes medication.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) prevention study

Participants 60 people

Who can join Ages 18–80 · all sexes

Timeline Started 2018-02 · est. completion 2024-12

Where 1 site · Greece

What this study is testing ClinicalTrials.gov NCT06611904 ↗

Description as written by the study sponsor.

Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness, UACR, endothelial glycocalyx and global longitudinal strain will be assesed at baseline, 4 and 12 months.

Treatments tested

Dulaglutide Drug

Combined treatment with dulaglutide and dapagliflozin
DPP-4 Inhibitors Drug

DPP-4i treatment as an add-on to metformin

Main thing measured	UACR
Sponsor	Attikon Hospital
Conditions studied	Urine Albumin (UAlb), Glycocalyx, Arterial Stiffness
GLP-1 drugs	dulaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06611904 ↗